Animal studies show experimental injection reverses osteoarthritis

Researchers at the University of Colorado Boulder have demonstrated that a single injected drug-delivery system can reverse osteoarthritis in animals within weeks. The team, led by chemical and biological engineer Stephanie Bryant, reported success in early animal experiments. They aim to advance to human trials after further safety testing.

A team from the University of Colorado Boulder has developed an experimental slow-release drug-delivery system that, when injected into damaged joints, prompts the body's cartilage and bone cells to repair osteoarthritis effectively in just weeks, according to ongoing animal experiments not yet peer-reviewed. Stephanie Bryant stated, 'In two years, we were able to go from a moonshot idea to developing these therapies to demonstrating that they reverse osteoarthritis in animals.' The researchers are now preparing for phase two, which will assess safety and toxicology to pave the way for human clinical trials within the next 18 months, pending results from additional animal studies. Bryant's goal is clear: 'not just to treat pain and halt progression, but to end this disease.' Currently, osteoarthritis—a condition affecting hundreds of millions worldwide with no cure—leaves patients managing pain or undergoing joint replacements. Evalina Burger, professor and chair of the Department of Orthopedics at UC Anschutz, noted, 'At the moment, the options for many patients are either a massive, expensive surgery or nothing. There's not a lot in between.' The team is also working on an injectable implant to recruit cells for cartilage repair, offering options for different stages of the disease. Funding comes from the Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program under ARPA-H, part of the US Department of Health and Human Services. ARPA-H Director Alicia Jackson said, 'Through ARPA-H, we are driving toward a future where people don't have to wake up in pain, give up activities they love, or face major surgeries and repeat joint replacements – so they can stay active, independent, and healthy for longer.'

Labaran da ke da alaƙa

Patient undergoing personalized gait retraining for knee osteoarthritis in a Stanford lab
Hoton da AI ya samar

Personalized foot-angle gait retraining reduced medial knee osteoarthritis pain in sham-controlled trial

An Ruwaito ta hanyar AI Hoton da AI ya samar An Binciki Gaskiya

In a randomized, sham-controlled trial, adults with mild-to-moderate medial compartment knee osteoarthritis who were retrained to walk with a personalized, small change in foot progression angle reported greater pain improvement after one year than those given sham retraining. The study, conducted at Stanford University and published in The Lancet Rheumatology, also found a smaller MRI-based worsening of a cartilage microstructure measure in the intervention group.

Promising animal studies from University of Colorado Boulder offer hope for osteoarthritis patients through a single injection that repairs damaged joints in weeks. Affecting one in six people over 30—with no cure—the disease limits daily activities, but this therapy targets root causes beyond pain management or surgery.

An Ruwaito ta hanyar AI

A one-year course of the drug abatacept can delay the onset of rheumatoid arthritis by up to four years in high-risk individuals. The benefits persisted long after treatment stopped, according to new research from King's College London.

A widely studied anti-aging treatment triggered significant brain damage in mice, according to new research from the University of Connecticut. The drug combination dasatinib plus quercetin caused myelin loss and changes resembling those seen in multiple sclerosis. The findings raise questions about its use in longevity studies and off-label therapies.

An Ruwaito ta hanyar AI

A single injection of gene therapy has significantly improved hearing in all ten patients born with a genetic form of deafness, according to a new study. Researchers delivered a working copy of the OTOF gene into the inner ear, with most patients regaining hearing within one month. The treatment, tested in China, proved safe and effective across ages from one to 24.

Wannan shafin yana amfani da cookies

Muna amfani da cookies don nazari don inganta shafin mu. Karanta manufar sirri mu don ƙarin bayani.
Ƙi